Skip to Main Content
Contribute Try STAT+ Today

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far, especially given recent events. But what choice do we have? After all, the world keeps spinning and, candidly, the alternatives are rather unpleasant. So time to buckle up and get cracking. On that note, we humbly present a few items of interest in hopes of moving you along productively on your journey today. Meanwhile, we encourage you to keep in touch — we enjoy saucy tips — and to stay safe. Wear a mask. …

Russia’s Sputnik V vaccine is 92% effective at protecting people from Covid-19, Fox News says. The interim results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, according to the Russian Direct Investment Fund, which has been backing the vaccine and marketing it globally. The Russian trial will continue for six more months and data from the trial will also be published in a leading international medical journal following peer review.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.